PathDigest @path_digest

aipoch-3A50

Is fungal pathology in the 21st pathology all about just writing a comment that says you're going to defer to cultures? Read this paper for a more nuanced approach: pubmed.ncbi.nlm.nih.gov/41248033/

Excited to share our latest work published in @IJGynP! PRAME IHC is highly sensitive and specific for distinguishing endometrial from endocervical adenocarcinomas, with strong concordance to mRNA expression. A practical adjunct in challenging cases and tumors of uncertain primary. #GynPathology Link 👉🏻 journals.lww.com/intjgynpatholo…

Rosai-Dorfman disease in skin -somebody please call the police - the emperipolice! An S100 protein stain highlights the nuclei (arrow) and cytoplasm of abnormal histiocytes but not the engulfed inflammatory cells in the cytoplasm (emperipolesis - engulfment without destruction).

keyboard_arrow_left Previous keyboard_arrow_right Next

The AI Scientist: Towards Fully Automated AI Research, Now Published in Nature Nature: nature.com/articles/s4158… Blog: sakana.ai/ai-scientist-n… When we first introduced The AI Scientist, we shared an ambitious vision of an agent powered by foundation models capable of executing the entire machine learning research lifecycle. From inventing ideas and writing code to executing experiments and drafting the manuscript, the system demonstrated that end-to-end automation of the scientific process is possible. Soon after, we shared a historic update: the improved AI Scientist-v2 produced the first fully AI-generated paper to pass a rigorous human peer-review process. Today, we are happy to announce that “The AI Scientist: Towards Fully Automated AI Research,” our paper describing all of this work, along with fresh new insights, has been published in @Nature! This Nature publication consolidates these milestones and details the underlying foundation model orchestration. It also introduces our Automated Reviewer, which matches human review judgments and actually exceeds standard inter-human agreement. Crucially, by using this reviewer to grade papers generated by different foundation models, we discovered a clear scaling law of science. As the underlying foundation models improve, the quality of the generated scientific papers increases correspondingly. This implies that as compute costs decrease and model capabilities continue to exponentially increase, future versions of The AI Scientist will be substantially more capable. Building upon our previous open-source releases (github.com/SakanaAI/AI-Sc…), this open-access Nature publication comprehensively details our system's architecture, outlines several new scaling results, and discusses the promise and challenges of AI-generated science. This substantial milestone is the result of a close and fruitful collaboration between researchers at Sakana AI, the University of British Columbia (UBC) and the Vector Institute, and the University of Oxford. Congrats to the team! @_chris_lu_ @cong_ml @RobertTLange @_yutaroyamada @shengranhu @j_foerst @hardmaru @jeffclune

Congratulations to Daniel M. Berney on receiving the #ISUP David J. Grignon Excellence in Education Award 🏅Honoring outstanding leadership, innovation, and global impact in urological pathology education. #USCAP2026 @daniel_berney

This is a paradigm shift - future neoadjuvant ( post neaoadjuvant ) clinical trials should consider ctDNA instead of pCR !

Kazuki Nozawa, MD @kazuki_nozawa

3 months ago

pCR after neoadjuvant chemotherapy has long been considered a strong prognostic marker. But adding ultra-sensitive ctDNA changes the picture. In the PREDICT-DNA trial (NeXT Personal @PersonalisInc ), ctDNA-negative patients among non-pCR cases showed outcomes comparable to pCR.

3 74 191 31K 93

#GUPath #Surgpath #Pathtwitter #PathX #Pathresidents: Let’s take a look at two biopsy cores (from the same patient) and decide what to call them. Take a look at both cases (“A” in this post, “B” in reply). Cast your vote. Then, read on for some teaching points geared towards trainees and general fans of #GUPath.

keyboard_arrow_left Previous keyboard_arrow_right Next

All the things that "LazySlide" does with a whole-slide image @naturemethods nature.com/articles/s4159…

The WHO #BlueBooks 6th ed. is coming out! Updates are based on current research and evidence - based. Each volume has an editor from a resource challenged setting. Increased harmonisation across volumes is pursued. Most entities include WSI’s . #GI6th & #Breast6th #Pathology

keyboard_arrow_left Previous keyboard_arrow_right Next

Delighted to share results of phase 2 ILUSTRO in @NatureMedicine @KlempnerSam @ASCOPost Zolbetuximab+FOLFOX+nivo showed encouraging activity in CLDN18.2+ gastric cancer with mPFS 14.8 months (18months in high CLDN). Supporting the ongoing phase 3 LUCERNA. doi.org/10.1038/s41591…

New in #HumPathol: The Impact of Next Generation Sequencing Studies on the Diagnosis of BAP1 Inactivated Melanocytic Tumors. sciencedirect.com/science/articl… #pathology #PathTwitter #PathX #dermpath

We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care.

Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer - ⁦@ASCOPost⁩ ascopost.com/news/march-202…

Artificial intelligence may help pave the way toward more equitable access to precision oncology! Genomic risk tools such as Oncotype DX play a key role in early-stage breast cancer by helping estimate prognosis and the likelihood of benefit from chemotherapy. However, their high cost and logistical barriers mean that many patients worldwide cannot access these tests. In this study, researchers developed an AI model that analyzes routine H&E pathology slides to predict the Oncotype DX recurrence score. Using data from the TAILORx trial, the model was able to classify patients into low-, intermediate-, and high-risk groups. These AI-derived risk groups were associated with recurrence risk and were also able to identify patients who derived greater benefit from chemotherapy. In other words, AI analysis of standard pathology images can capture much of the prognostic and predictive information provided by genomic assays. thelancet.com/journals/lanon…

🧵 NEW PAPER ALERT! Excited to share our work on immunophenotypic changes after menin inhibition in AML, just published in @LeukemiaJnl 🩸 nature.com/articles/s4137… #hemepath #leusm #AML #meninInhibitor #revumenib

Here's the direct link to PathDigest: pathdigest.com Let me know what you think!

Every day, hundreds of new pathology papers drop across 65+ journals. Nobody has time to track them all. PathDigest does it for you — one clean daily feed with AI summaries, filtered by subspecialty, organ site & article type. Surgical pathology, cytopathology, GI, dermpath, heme, breast… all in one place. If you read slides for a living, this belongs in your workflow. #PathTwitter #Pathology #SurgicalPathology

New in @Human_Pathology: ✌🏻 reviews in the 2026 Pathology Updates issue on GU pathology—bladder, prostate, kidney, testis, and penile tumors. Grateful to great co-authors—hope it’s useful for pathologists and trainees! 🔗 sciencedirect.com/science/articl… 🔗 sciencedirect.com/science/articl…

keyboard_arrow_left Previous keyboard_arrow_right Next

Human Pathology @Human_Pathology

3 months ago

The March 2026 issue of Human Pathology is available online! sciencedirect.com/journal/human-… #pathology #HumPathol #PathTwitter #PathX

0 6 26 5K 12

“The TP53 gene contains a diversity box that makes it more than a tumor suppressor” Find this informative and well-constructed review here: rdcu.be/e7boq